Results 201 to 207 of about 11,226 (207)

<p>Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy</p>

Cancer Management and Research, 2020
Danai Dima, Joshua Dower, Raymond L Comenzo   +2 more
exaly  

Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature

Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020
Ramon Lecumberri, Isabel Krsnik, Adrian Alegre   +2 more
exaly  

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

Advances in Therapy, 2018
Xu Steven Xu, Pieter Sonneveld, P Joy Ho   +2 more
exaly  

Daratumumab

Reactions Weekly, 2016
openaire   +1 more source

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

Blood, 2016
Larry J Suva, Niels Weinhold, Leo Rasche   +2 more
exaly  

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients

Cancer, 2019
Ajay K Nooka, Nisha S Joseph, Jonathan L Kaufman   +2 more
exaly  

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine
Inger S Nijhof, Tobias Silzle, Tahamtan Ahmadi   +2 more
exaly